Interpreting the results of rapid molecular diagnostic tests for carbapenem-resistant Enterobacterales infection: current clinical perspective while waiting for further evidence

References

• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing enterobacteriaceae. Clin Microbiol Infect. 2014 Sep;20(9):862–872. doi: 10.1111/1469-0691.12697
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Papoutsaki V, et al. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2022 Jan;20(1):53–69. doi: 10.1080/14787210.2021.1935237
   PubMed Web of Science ®Google Scholar
• Isler B, Aslan AT, Akova M, et al. Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections. Expert Rev Anti Infect Ther. 2022 Nov;20(11):1389–1400. doi: 10.1080/14787210.2022.2128764
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018 Feb;24(2):133–144. doi: 10.1016/j.cmi.2017.08.030
   PubMed Web of Science ®Google Scholar
• Bassetti M, Di Pilato V, Giani T, et al. Treatment of severe infections due to metallo-β-lactamases-producing gram-negative bacteria. Future Microbiol. 2020 Nov;3(15):1489–1505. doi: 10.2217/fmb-2020-0210
   Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. Pharmacotherapy. 2019 Jan;39(1):10–39. doi: 10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Corcione S, Grossi A, et al. The impact of carbapenem resistance on mortality in patients with Klebsiella Pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Ther. 2021 Mar;10(1):541–558. doi: 10.1007/s40121-021-00408-8
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Di Pilato V, Karaiskos I, et al. Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades. Ann Med. 2023 Dec;55(1):101–113. doi: 10.1080/07853890.2022.2152484
   PubMed Web of Science ®Google Scholar
• Karvouniaris M, Almyroudi MP, Abdul-Aziz MH, et al. Novel antimicrobial agents for gram-negative pathogens. Antibiotics (Basel). [2023 Apr 16];12(4):761. doi: 10.3390/antibiotics12040761
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Marelli C, Cattardico G, et al. Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape. J Antimicrob Chemother. [2023 Oct 3];78(10):2505–2514. doi: 10.1093/jac/dkad262
   PubMed Web of Science ®Google Scholar
• Zhang S, Liao X, Ding T, et al. Role of β-lactamase inhibitors as potentiators in antimicrobial chemotherapy targeting gram-negative bacteria. Antibiotics. 2024;13(3):260. doi: 10.3390/antibiotics13030260
   Google Scholar
• Giacobbe DR, Bassetti M. Innovative β-Lactam/β-lactamase inhibitor combinations for carbapenem-resistant gram-negative bacteria. Future Microbiol. 2022 Apr;17(6):393–396. doi: 10.2217/fmb-2021-0301
   PubMed Web of Science ®Google Scholar
• Moerman A, De Waele JJ, Boelens J. An overview of point-of-care testing for infections in critically ill patients. Expert Rev Mol Diagn. 2024 Mar;24(3):193–200. doi: 10.1080/14737159.2024.2322146
   PubMed Web of Science ®Google Scholar
• Dessajan J, Timsit JF. Impact of multiplex PCR in the therapeutic management of severe bacterial pneumonia. Antibiotics (Basel). [2024 Jan 18];13(1):95. doi: 10.3390/antibiotics13010095
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant gram-negative bacteria: therapeutic implications. Clin Microbiol Infect. 2020 Jun;26(6):713–722. doi: 10.1016/j.cmi.2019.09.023
   PubMed Web of Science ®Google Scholar
• Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev. 2018 Jan;31(1). doi: 10.1128/CMR.00024-17
   PubMed Web of Science ®Google Scholar
• Enne VI, Aydin A, Baldan R, et al. Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. Thorax. 2022 Dec;77(12):1220–1228. doi: 10.1136/thoraxjnl-2021-216990
   PubMed Web of Science ®Google Scholar
• Messacar K, Hurst AL, Child J, et al. Clinical impact and provider acceptability of real-time antimicrobial stewardship decision support for rapid diagnostics in children with positive Blood culture results. J Pediatric Infect Dis Soc. [2017 Sep 1];6(3):267–274. doi: 10.1093/jpids/piw047
   PubMed Web of Science ®Google Scholar
• Buss BA, Baures TJ, Yoo M, et al. Impact of a multiplex PCR assay for bloodstream infections with and without antimicrobial stewardship intervention at a cancer hospital. Open Forum Infect Dis. 2018 Oct;5(10):ofy258. doi: 10.1093/ofid/ofy258
   PubMed Web of Science ®Google Scholar
• Bookstaver PB, Nimmich EB, Smith TJ 3rd, et al. Cumulative effect of an antimicrobial stewardship and rapid diagnostic testing bundle on early streamlining of antimicrobial therapy in gram-negative bloodstream infections. Antimicrob Agents Chemother. 2017 Sep;61(9). doi: 10.1128/AAC.00189-17
   Web of Science ®Google Scholar
• Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol. 2016 Mar;54(3):687–698. doi: 10.1128/JCM.01679-15
   PubMed Web of Science ®Google Scholar
• Burrack-Lange SC, Personne Y, Huber M, et al. Multicenter assessment of the rapid unyvero blood culture molecular assay. J Med Microbiol. 2018 Sep;67(9):1294–1301. doi: 10.1099/jmm.0.000804
   PubMed Web of Science ®Google Scholar
• Monard C, Pehlivan J, Auger G, et al. Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. Crit Care. [2020 Jul 14];24(1):434. doi: 10.1186/s13054-020-03114-y
   PubMed Web of Science ®Google Scholar
• Peiffer-Smadja N, Bouadma L, Mathy V, et al. Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia. Crit Care. [2020 Jun 19];24(1):366. doi: 10.1186/s13054-020-03067-2
   PubMed Web of Science ®Google Scholar
• Mo Y. Rapid diagnostics for antibiotic resistance: urgent need for strong clinical evidence. Clin Infect Dis. [2022 Dec 19];75(12):2076–2078. doi: 10.1093/cid/ciac358
   PubMed Web of Science ®Google Scholar
• Poole S, Tanner AR, Naidu VV, et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: results of a randomised controlled trial. J Infect. 2022 Dec;85(6):625–633. doi: 10.1016/j.jinf.2022.09.003
   PubMed Web of Science ®Google Scholar
• High J, Enne VI, Barber JA, et al. INHALE: the impact of using FilmArray pneumonia panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK critical care-study protocol for a multicentre randomised controlled trial. Trials. [2021 Oct 7];22(1):680. doi: 10.1186/s13063-021-05618-6
   PubMed Web of Science ®Google Scholar
• Fartoukh M, Nseir S, Megarbane B, et al. Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial. Clin Microbiol Infect. 2023 Jun;29(6):734–743. doi: 10.1016/j.cmi.2023.01.009
   PubMed Web of Science ®Google Scholar
• Enne V, Stirling S, Barber J, et al. LB2304. INHALE WP3: results of a multi-centre randomised controlled trial (INHALE) testing the utility of rapid multiplex PCR at point-of-care for the antibiotic management of hospital-acquired and ventilator-associated pneumonia in critical care. Open Forum Infect Dis. 2022;9(Supplement_2):ofac492.1894. doi: 10.1093/ofid/ofac492.1894
   Google Scholar
• Darie AM, Khanna N, Jahn K, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of gram-negative bacterial infection (flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022 Sep;10(9):877–887. doi: 10.1016/S2213-2600(22)00086-8
   PubMed Web of Science ®Google Scholar
• Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. [2015 Oct 1];61(7):1071–1080. doi: 10.1093/cid/civ447
   PubMed Web of Science ®Google Scholar
• Rule R, Paruk F, Becker P, et al. Clinical utility of the BioFire FilmArray Blood culture identification panel in the adjustment of empiric antimicrobial therapy in the critically ill septic patient. PLOS ONE. 2021;16(7):e0254389. doi: 10.1371/journal.pone.0254389
   PubMed Web of Science ®Google Scholar
• Maataoui N, Chemali L, Patrier J, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2227–2234. doi: 10.1007/s10096-021-04213-6
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Crea F, Morici P, et al. T2Bacteria and T2Resistance assays in critically Ill patients with sepsis or septic shock: a descriptive experience. Antibiotics (Basel). [2022 Dec 15];11(12):1823. doi: 10.3390/antibiotics11121823
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clin Infect Dis. [2022 Dec 19];75(12):2066–2075. doi: 10.1093/cid/ciac354
   PubMed Web of Science ®Google Scholar
• Galani I, Karaiskos I, Giamarellou H. Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel beta-lactam-beta-lactamase inhibitor combinations. Expert Rev Anti Infect Ther. 2021 Nov;19(11):1457–1468. doi: 10.1080/14787210.2021.1924674
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Pollini S, Miriagou V, et al. Carbapenem-resistant Klebsiella pneumoniae: the role of plasmids in emergence, dissemination, and evolution of a major clinical challenge. Expert Rev Anti Infect Ther. 2024 Jan;22(1–3):25–43. doi: 10.1080/14787210.2024.2305854
   PubMed Web of Science ®Google Scholar
• Hobson CA, Cointe A, Jacquier H, et al. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC beta-lactamase mutants and the inoculum effect. Clin Microbiol Infect. 2021 Aug;27(8):e1172 7–e1172 10. doi: 10.1016/j.cmi.2021.04.016
   Web of Science ®Google Scholar
• Di Pilato V, Principe L, Andriani L, et al. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Clinical Microbiology Infection. 2023 Apr;29(4):.e537.1–.e537.8. doi: 10.1016/j.cmi.2022.11.011
   Web of Science ®Google Scholar